# Carcinoma, Non-Small-Cell Lung FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/carcinoma-non-small-cell-lung

> 28 upcoming FDA catalysts in carcinoma, Non-Small-Cell Lung: KEYTRUDA® (pembrolizumab, MRK) on Jan to Apr 2027 (topline data readout); KEYTRUDA® (pembrolizumab, MRK) on January 2027 (primary completion); AUGTYRO (repotrectinib, BMY) on Feb to May 2027 (topline data readout); AUGTYRO (repotrectinib, BMY) on February 2027 (primary completion); and 24 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| October 31, 2025 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Carcinoma, Non-Small-Cell Lung | completed | "NCT04165083 (KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-31 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-10-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04165083)) |
| January 12, 2026 | [Retevmo (selpercatinib) primary completion](https://sec-api.dev/pdufa/selpercatinib) | LLY | Carcinoma, Non-Small-Cell Lung | completed | "NCT04819100 (A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-01-12 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04819100)) |
| May 18, 2026 | [Sigvotatug vedotin primary completion](https://sec-api.dev/pdufa/sigvotatug-vedotin) | PFE | Carcinoma, Non-Small-Cell Lung | completed | "NCT06012435 (A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-05-18 (ACTUAL); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06012435)) |
| June 15, 2026 | [Pembrolizumab/vibostolimab primary completion](https://sec-api.dev/pdufa/pembrolizumab-vibostolimab) | MRK | Carcinoma, Non-Small-Cell Lung | completed | "NCT05298423 (Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-15 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05298423)) |
| July 6, 2026 | [Tagrisso® (osimertinib) primary completion](https://sec-api.dev/pdufa/osimertinib) | AZN | Carcinoma; Non-Small-Cell Lung | completed | "NCT05261399 (Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-06 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05261399)) |
| Oct 2026 to Jan 2027 | [Imfinzi® (durvalumab) topline data readout](https://sec-api.dev/pdufa/durvalumab) | AZN | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT06008093 (A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-27 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06008093)) |
| October 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Carcinoma, Non-Small-Cell Lung | delayed | "NCT06008093 (A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-27 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06008093)) |
| October 29, 2026 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Carcinoma, Non-Small-Cell Lung | completed | "NCT04165083 (KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-31 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-10-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04165083?tab=results)) |
| Jan to Apr 2027 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT05609968 (Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-12 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05609968)) |
| January 2027 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT05609968 (Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-12 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05609968)) |
| Feb to May 2027 | [AUGTYRO (repotrectinib) topline data readout](https://sec-api.dev/pdufa/repotrectinib) | BMY | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT06140836 (A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-16 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06140836)) |
| February 2027 | [AUGTYRO (repotrectinib) primary completion](https://sec-api.dev/pdufa/repotrectinib) | BMY | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT06140836 (A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-16 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06140836)) |
| May to Aug 2027 | [Lazcluze (lazertinib mesylate) topline data readout](https://sec-api.dev/pdufa/lazertinib) | JNJ | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT06120140 (Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-31 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06120140)) |
| May 2027 | [Lazcluze (lazertinib mesylate) primary completion](https://sec-api.dev/pdufa/lazertinib) | JNJ | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT06120140 (Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-31 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06120140)) |
| Jul to Oct 2027 | [6-thio-2'-deoxyguanosine topline data readout](https://sec-api.dev/pdufa/6-thio-2-deoxyguanosine) | MAIA | Carcinoma, Non-Small -Cell Lung | scheduled | "NCT06908304 (A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-31 (ESTIMATED); Lead Sponsor Maia Biotechnology." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06908304)) |
| July 2027 | [6-thio-2'-deoxyguanosine primary completion](https://sec-api.dev/pdufa/6-thio-2-deoxyguanosine) | MAIA | Carcinoma, Non-Small -Cell Lung | scheduled | "NCT06908304 (A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-31 (ESTIMATED); Lead Sponsor Maia Biotechnology." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06908304)) |
| Aug to Nov 2027 | [Lazcluze (lazertinib mesylate) topline data readout](https://sec-api.dev/pdufa/lazertinib) | JNJ | Carcinoma, Non-small-Cell Lung | scheduled | "NCT05498428 (A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08-17 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05498428)) |
| August 2027 | [Lazcluze (lazertinib mesylate) primary completion](https://sec-api.dev/pdufa/lazertinib) | JNJ | Carcinoma, Non-small-Cell Lung | scheduled | "NCT05498428 (A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08-17 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05498428)) |
| Sep to Dec 2027 | [6-thio-2'-deoxyguanosine topline data readout](https://sec-api.dev/pdufa/6-thio-2-deoxyguanosine) | MAIA | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT05208944 (THIO Sequenced With Cemiplimab in Advanced NSCLC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Maia Biotechnology." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05208944)) |
| September 2027 | [6-thio-2'-deoxyguanosine primary completion](https://sec-api.dev/pdufa/6-thio-2-deoxyguanosine) | MAIA | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT05208944 (THIO Sequenced With Cemiplimab in Advanced NSCLC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Maia Biotechnology." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05208944)) |
| Mar to Jun 2028 | [Lazcluze (lazertinib mesylate) topline data readout](https://sec-api.dev/pdufa/lazertinib) | JNJ | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT07586202 (A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-02 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07586202)) |
| March 2028 | [Lazcluze (lazertinib mesylate) primary completion](https://sec-api.dev/pdufa/lazertinib) | JNJ | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT07586202 (A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-02 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07586202)) |
| Oct 2028 to Jan 2029 | [Imfinzi® (durvalumab) topline data readout](https://sec-api.dev/pdufa/durvalumab) | AZN | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT03833154 (Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-10-31 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03833154)) |
| October 2028 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT03833154 (Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-10-31 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03833154)) |
| Dec 2028 to Mar 2029 | [JNJ-90301900 topline data readout](https://sec-api.dev/pdufa/jnj-90301900) | JNJ | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT06667908 (A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12-31 (ESTIMATED); Lead Sponsor Johnson & Johnson Enterprise Innovation Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06667908)) |
| Dec 2028 to Mar 2029 | [Navlimetostat topline data readout](https://sec-api.dev/pdufa/navlimetostat) | BMY | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT06855771 (A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12-29 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06855771)) |
| December 2028 | [Navlimetostat primary completion](https://sec-api.dev/pdufa/navlimetostat) | BMY | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT06855771 (A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12-29 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06855771)) |
| December 2028 | [JNJ-90301900 primary completion](https://sec-api.dev/pdufa/jnj-90301900) | JNJ | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT06667908 (A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12-31 (ESTIMATED); Lead Sponsor Johnson & Johnson Enterprise Innovation Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06667908)) |
| May to Aug 2029 | [Lazcluze (lazertinib mesylate) topline data readout](https://sec-api.dev/pdufa/lazertinib) | JNJ | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT06667076 (A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05-23 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06667076)) |
| May 2029 | [Olomorasib primary completion](https://sec-api.dev/pdufa/olomorasib) | LLY | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT06890598 (Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06890598)) |
| May to Aug 2029 | [Olomorasib topline data readout](https://sec-api.dev/pdufa/olomorasib) | LLY | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT06890598 (Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06890598)) |
| May 2029 | [Lazcluze (lazertinib mesylate) primary completion](https://sec-api.dev/pdufa/lazertinib) | JNJ | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT06667076 (A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05-23 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06667076)) |
| Sep to Dec 2029 | [Krazati (adagrasib) topline data readout](https://sec-api.dev/pdufa/adagrasib) | BMY | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT06875310 (A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-07 (ESTIMATED); Lead Sponsor Mirati Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06875310)) |
| September 2029 | [Krazati (adagrasib) primary completion](https://sec-api.dev/pdufa/adagrasib) | BMY | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT06875310 (A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-07 (ESTIMATED); Lead Sponsor Mirati Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06875310)) |
| Jan to Apr 2030 | [Rilvegostomig topline data readout](https://sec-api.dev/pdufa/rilvegostomig) | AZN | Carcinoma, Non-Small Cell Lung | scheduled | "NCT06868277 (A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-01-17 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06868277)) |
| January 2030 | [Rilvegostomig primary completion](https://sec-api.dev/pdufa/rilvegostomig) | AZN | Carcinoma, Non-Small Cell Lung | scheduled | "NCT06868277 (A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-01-17 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06868277)) |

## Drugs

- [KEYTRUDA® (pembrolizumab)](https://sec-api.dev/pdufa/pembrolizumab) (MRK)
- [Retevmo (selpercatinib)](https://sec-api.dev/pdufa/selpercatinib) (LLY)
- [Sigvotatug vedotin](https://sec-api.dev/pdufa/sigvotatug-vedotin) (PFE)
- [Pembrolizumab/vibostolimab](https://sec-api.dev/pdufa/pembrolizumab-vibostolimab) (MRK)
- [Tagrisso® (osimertinib)](https://sec-api.dev/pdufa/osimertinib) (AZN)
- [Imfinzi® (durvalumab)](https://sec-api.dev/pdufa/durvalumab) (AZN)
- [AUGTYRO (repotrectinib)](https://sec-api.dev/pdufa/repotrectinib) (BMY)
- [Lazcluze (lazertinib mesylate)](https://sec-api.dev/pdufa/lazertinib) (JNJ)
- [6-thio-2'-deoxyguanosine](https://sec-api.dev/pdufa/6-thio-2-deoxyguanosine) (MAIA)
- [JNJ-90301900](https://sec-api.dev/pdufa/jnj-90301900) (JNJ)
- [Navlimetostat](https://sec-api.dev/pdufa/navlimetostat) (BMY)
- [Olomorasib](https://sec-api.dev/pdufa/olomorasib) (LLY)
- [Krazati (adagrasib)](https://sec-api.dev/pdufa/adagrasib) (BMY)
- [Rilvegostomig](https://sec-api.dev/pdufa/rilvegostomig) (AZN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/carcinoma-non-small-cell-lung.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Carcinoma, Non-Small-Cell Lung FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/carcinoma-non-small-cell-lung

```bibtex
@misc{secapidev_indications_carcinoma_non_small_cell_lung_20261116,
  title        = {Carcinoma, Non-Small-Cell Lung FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/carcinoma-non-small-cell-lung}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_carcinoma_non_small_cell_lung_20261116","title":"Carcinoma, Non-Small-Cell Lung FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/carcinoma-non-small-cell-lung","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
